Key result
At clinically relevant maximum blood concentrations, lipophilic pitavastatin (250 nM) significantly inhibited phenylephrine-induced cardiomyocyte hypertrophy and cardiac fibrosis, whereas hydrophilic rosuvastatin (50 nM) did not.
Why the study?
Differences between lipophilic pitavastatin and hydrophilic rosuvastatin on plasma BNP suggested that statin lipophilicity and pharmacokinetics alter pleiotropic effects on heart failure.
Does pitavastatin reduce cardiomyocyte hypertrophy and cardiac fibrosis compared to rosuvastatin in cultured cardiac cells?
Does pitavastatin reduce cardiomyocyte hypertrophy and cardiac fibrosis compared to rosuvastatin in cultured cardiac cells?
Answers are grounded in this paper and cite their sources.
At clinically relevant doses, lipophilic pitavastatin, but not hydrophilic rosuvastatin, directly inhibits cardiomyocyte hypertrophy and cardiac fibrosis in vitro.
Clinical studies have indicated that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, can potentially inhibit chronic heart failure. In the Stat-LVDF study, a difference was noted in terms of the effect of lipophilic pitavastatin (PTV) and hydrophilic rosuvastatin (RSV) on plasma BNP, suggesting that statin lipophilicity and pharmacokinetics change the pleiotropic effect on heart failure in humans. Therefore, we assessed the beneficial effects of PTV on hypertrophy in cardiac myocytes compared with RSV at clinically used doses. Cultured cardiomyocytes were stimulated with 30 μM phenylephrine (PE) in the presence of PTV (250 nM) or RSV (50 nM). These doses were calculated based on the maximum blood concentration of statins used in clinical situations in Japan. The results showed that PTV, but not RSV, significantly inhibits the PE-induced increase in cell size and leucine incorporation without causing cell toxicity. In addition, PTV significantly suppressed PE-induced mRNA expression of hypertrophic response genes. PE-induced ERK phosphorylation was inhibited by PTV, but not by RSV. Furthermore, PTV significantly suppressed the angiotensin-II-induced proline incorporation in primary cultured cardiac fibroblasts. In conclusion, a clinical dose of PTV was noted to directly inhibit cardiomyocyte hypertrophy and cardiac fibrosis, suggesting that lipophilic PTV can be a potential drug candidate against chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Katanasaka et al. (2021) studied Cardiomyocyte hypertrophy and cardiac fibrosis. Pitavastatin vs. Rosuvastatin (50 nM) and untreated controls was evaluated on Phenylephrine-induced increase in cardiomyocyte cell size (p=<0.001). At clinically relevant maximum blood concentrations, lipophilic pitavastatin (250 nM) significantly inhibited phenylephrine-induced cardiomyocyte hypertrophy and cardiac fibrosis, whereas hydrophilic rosuvastatin (50 nM) did not.
Synapse has enriched 10 related papers. Consider them for comparative context: